Complex coronary cases
Protected Multivessel PCI with Impella LV Assist Device – March 2017

Views 2890

56 year old diabetic male presented with angina equivalent dyspnea, left heart failure and a positive SPECT MPI for multivessel infarction (70%) and ischemia (30%). A Cardiac Cath on February 7, 2017 revealed 3 V CAD: total occlusion of mid RCA, total occlusion of mid LAD, 90% LCx-OM1 with SYNTAX Score of 28 and severe LV dysfunction LVEF 28%. Patient underwent cardiac MRI, which revealed subendocardial myocardial infarction of interior and inferolateral segments, transmural infarct involving apex and substantial viability of numerous myocardial segments. Patient underwent Heart Team discussion and CABG was declined due to diffuse CAD and patient’s preference for PCI. Patient has been optimized on guided medical therapy. Patient is now planned for protected multivessel PCI with Impella LV assist device.

55:23

Q&A
Q
What will be the practical benefits of iFR?
A.

Most important benefit of iFR is no need of adenosine and utility in serial lesion measurement post PCI.


Q
Cost? Considering since there is a sole company, there is almost a monopoly?
A.

The cost of iFR wire is similar to FFR wire which is around $650. Overall iFR procedure cost will be few hundred $ less then FFR measurement due to cost savings of adenosine (around $200) and 5-10 minutes of shorter procedure time. Despite being proprietary technology owned by Volcano and now Phillips, I doubt that iFR price will increase. It still needs to be approved by various insurances as FFR approval took 1-2 years after being used liberally post FAME trials.


Q
Are these two publications a death nail for FFR?
A.

I predict that overall use of physiological assessment will increase after these two iFR trials; recent ACC-NCDR data showed that only 28% of PCIs are being done with FFR guidance. iFR use will take away the issue of adenosine intolerance in 15-20% of cases.


Q
Or, these will be complimentary technologies?
A.

Both will be additive and complimentary as some will continue to use FFR and some will change to iFR or new start of the technique.


Q
Between the two, which is a better prognosticator?
A.

Based on these 2 major RCT, both are equal from prognosis and f/u MACE at 1 year point of view.


Q
Are the new AUC Guidelines a positive, a negative or neutral?
A.

New AUC guidelines for stable CAD is superb addition to this field as authors have addressed numerous outstanding issues encountered in daily practice and were lacking in the earlier documents.


Q
Is the reporting not too complicated?
A.

I agree that current report is slightly more complicated but more explicit also and we just need to retrain ourselves in the new classification.


Q
In a desire to self-regulate, is the pendulum not swinging too much towards curbing PCI?
A.

Actually pendulum is swinging against any revascularization (PCI or CABG) with special emphasis on MMT/GMT. This we have seen in NY state where both PCI and CABG are declining.


Q
Are we not over regulating? Is there a need for such severe self-reporting simply to arm insurers to deny coverage? You do not see such reporting in other specialties?
A.

I fully agree and as outlined in the document, that AUC should not be used to deny payment for a clinical condition; hence the word used now is 'rarely appropriate care' rather then earlier Inappropriate care.


Q
There are also medico-legal implications of such reporting - after all, were the guidelines not sufficient for this purpose?
A.

I will say that current AUC terminology has less medico legal ramification and hence is a positive effort.


comments

Leave a Reply

Your email address will not be published. Required fields are marked *

suggestion
Suggestions
Radial PCI of Long Complex Calcified LAD post TAVR – September 2020
Views 58

Case and Plan: 78 year-old-male presented on August 7, 2020 with progressive exertional dyspnea, NYHA class III. Workup revealed severe AS (AVA 0.7cm2), normal LV function and STS mortality of 1.1%. After heart team discussion, patient underwent successful TAVR using 26mm SAPIEN-3 Ultra with excellent results, AV area of 2.0cm2 and no PVL. A coronary […]


Stent Ablation with RA of Underexpanded Multilayer DES – August 2020
Tags: | |
Views 309

63 year-old male with known CAD, CABG x2 (1999) and multiple PCI’s to SVG to RCA and LCx branches presented with CCS Class IV angina and non-STEMI (TnI 1.2U). A Cardiac Cath on June 22, 2020 revealed patent LIMA to LAD, non obstructive LCx branches with patent prior stents and 90% multilayer in-stent restenosis of […]


Imaging Guided PCI of DES CTO RCA – July 2020
Views 645

57 year-old male with extensive CAD and PCI’s presented with crescendo angina on 8/20/2019 and Cath revealed 3 V CAD with DES CTO of RCA and normal LV function. CABG was recommended, but declined and patient did well on MMT. Recently started having angina and underwent Rota DES PCI of LAD/D1 bifurcation. Now planned for […]


IVUS Guided Orbital Atherectomy and DES of Tortuous Calcified LAD – June 2020
Views 690

Case and Plan: 72-year-old male presented with rest angina and Non-STEMI, peak TnI 7.6. A Cardiac Cath on February 6, 2020 revealed 3 V CAD: 95% ulcerated proximal RCA, severely calcified 80-90% proximal and mid LAD, 80% proximal LCx, 70% proximal Ramus Intermedius with LVEF 45% and SYNTAX Score of 32. Patient underwent successful culprit […]